Evidence map›Paper›PMID 40678242›Full record

ArticleResearch square2025

Global C3 lowering in adulthood protects against hippocampal dysfunction and cognitive impairment in aged mice.

Andre F Batista, Jessey Presumey, Brijendra Singh, Maren K Schroeder, Khyrul Khan, Emma Spooner, Shaomin Li, Michael C Carroll, Cynthia A Lemere

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andre F BatistaDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Jessey PresumeyProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Brijendra SinghDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Maren K SchroederDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Khyrul KhanDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Emma SpoonerDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Shaomin LiDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Michael C CarrollProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Cynthia A LemereDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.

Funding

Evolution of autoreactive GC and epitope spreading in lupusR01AR074105 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI Michael Craig Carroll · 2018 to 2026
$4.2M
Novel Inducible Complement C3 Conditional KO Mouse Models to Investigate Neurodegeneration in ADRF1AG060057 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI LEMERE, CYNTHIA A · 2018 to 2018
$3.4M
FDC regulation of self-reactive B cellsR01AI130307 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI CARROLL, MICHAEL CRAIG · 2018 to 2022
$2.7M
Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid ImmunotherapyR01NS136122 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI CYNTHIA A LEMERE · 2024 to 2026
$2.5M
Generation of a Complement C3 Conditional Knockout MouseR21AG044713 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI LEMERE, CYNTHIA A · 2013 to 2014
$475k
NIAID NIH HHS R01 AI130307NIAMS NIH HHS R01 AR074105NIA NIH HHS R21 AG044713NIA NIH HHS RF1 AG060057NINDS NIH HHS R01 NS136122
6 · The paper itself

Abstract

Background: Complement component 3 (C3) is increasingly recognized for its role in neurodegenerative processes; however, its specific impact on age-related hippocampal dysfunction remains poorly understood. This study investigates the effects of inducible C3 knockdown in adulthood on hippocampal function using a novel mouse model. Methods: We developed a chimeric floxed C3 mouse line ( Results: TAM treatment led to a sustained reduction in C3 levels in serum, liver, and brain tissues of Conclusion: Our C3iKO mouse model was consistently effective in lowering C3 levels in the brain and periphery in mice. The findings reported here demonstrate that global C3 lowering in adulthood, after brain development, protected the brain against age-associated hippocampal dysfunction and cognitive decline, suggesting that complement modulation may provide a neuroprotective strategy against brain aging. The

Indexed as

agingcognitive declineComplement C3 knockdownhippocampal dysfunctionsynapse loss

Identifiers

PMID40678242
PMCPMC12270239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.